Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Accumulated Expenses (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Accumulated Expenses for 12 consecutive years, with $4.4 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 125551.93% year-over-year to $4.4 million; the TTM value through Mar 2026 reached $4.4 million, up 125551.93%, while the annual FY2025 figure was $16.3 million, N/A changed from the prior year.
  • Accumulated Expenses hit $4.4 million in Q1 2026 for Crescent Biopharma, down from $16.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $16.3 million in Q4 2025 and bottomed at $3528.0 in Q1 2025.
  • Average Accumulated Expenses over 5 years is $4.1 million, with a median of $2.3 million recorded in 2023.
  • Year-over-year, Accumulated Expenses plummeted 99.38% in 2025 and then skyrocketed 125551.93% in 2026.
  • Crescent Biopharma's Accumulated Expenses stood at $300653.0 in 2022, then surged by 1638.07% to $5.2 million in 2023, then tumbled by 91.6% to $439130.0 in 2024, then soared by 3621.9% to $16.3 million in 2025, then crashed by 72.88% to $4.4 million in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.4 million, $16.3 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.